The Summary
Researchers conducted a systematic review and meta-analysis of 25 randomized controlled trials involving 6,812 participants to evaluate the melatoninergic antidepressant agomelatine against a placebo. While agomelatine did not significantly alter objective total sleep time, it significantly improved subjective sleep quality and reduced instances of insomnia. However, patients taking agomelatine experienced more daytime somnolence (drowsiness) and slightly more overall mild adverse effects. The researchers concluded that agomelatine is generally safe and moderately effective for sleep quality, though more robust data is needed.
Why this is interesting
Many people use agomelatine hoping its dual action on melatonin and serotonin receptors will effortlessly cure sleep issues. This study clarifies the reality: while it reliably improves how deep and restful your sleep feels and prevents insomnia, it won't actually lengthen your total sleep time. Plus, the increased daytime drowsiness means users should weigh nighttime benefits against daytime sluggishness. For patients, it highlights agomelatine as a helpful option for sleep quality rather than duration, offering a clearer picture for personalized treatment plans.